GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Celcuity Inc.
Shares of Celcuity, a biotech company developing new methods for cancer diagnostics and treatment, are extremely volatile. Their price is not driven by current revenue but rather reflects investors' speculative expectations regarding the results of clinical trials.
Share prices of companies in the market segment - Cancer analysis
Celcuity is a biotech company developing a platform for selecting optimal treatments for cancer patients. We classify it as part of the Cancer Analysis sector, and the chart below reflects the dynamics of the entire personalized medicine and diagnostics industry, where value is determined by the success of clinical data.
Broad Market Index - GURU.Markets
Celcuity is a biotech company developing diagnostic tests and targeted drugs for cancer treatment. Its integrated approach makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Celcuity compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CELC - Daily change in the company's share price Celcuity Inc.
Shares of Celcuity, a biotech company developing targeted cancer therapies, are highly volatile. Change_co measures the market's reaction to clinical trial data. This metric is an important component of formulas on System.GURU.Markets that evaluate innovative companies in the oncology sector.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Celcuity Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with CELC's performance, which depends on clinical trial results, helps to assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Celcuity is a biotech company developing a platform for personalized therapy for cancer patients. Oncology and AI are two highly volatile sectors. The chart below reflects the average fluctuations in this industry, providing context for assessing the risks and potential of Celcuity shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Celcuity Inc.
Celcuity is a biotech company specializing in cancer diagnostics and treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Celcuity Inc. is a biotech company developing a cell analysis platform that helps select targeted therapies for cancer patients. Its stock performance is entirely dependent on clinical trial results and partnerships. The chart reflects the high risks and potential for breakthroughs in personalized oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Celcuity is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new diagnostic tests for cancer treatment. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Celcuity Inc.
Celcuity, a biotech company developing targeted therapies for cancer, has sharp monthly fluctuations reflecting news about clinical trials of its drugs, a key factor for companies in the research and development stage.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Oncology diagnostics is one of the most research-intensive and risky biotech segments. Its market capitalization dynamics, shown in the chart, reflect investors' faith in new methods for fighting cancer. This is the backdrop against which companies like Celcuity are conducting research that could change treatment approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Celcuity is a biotech company developing targeted cancer therapies. Its shares are caught in a world of clinical data and regulatory announcements. Their price can rise or fall regardless of the broader market, demonstrating complete independence from general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Celcuity Inc.
Celcuity Inc. is a biotech company developing a cell analysis platform to help identify targeted therapies for cancer patients. Its weekly stock price is driven by news about clinical trials of its diagnostic tests and therapeutic candidates, which is typical for early-stage biotechs.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
As a clinical-stage biotech, Celcuity exists in its own universe. Its weekly performance is 100% dependent on clinical trial news, not on general pharmaceutical industry trends. The chart clearly demonstrates these sharp, sector-neutral ups and downs, typical of biotechs on the cusp of breakthroughs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Celcuity is a biotech company developing new methods for diagnosing and treating cancer. Its shares are eagerly awaiting clinical trial results. The chart clearly shows how much their performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
CELC - Market capitalization of the company Celcuity Inc.
Celcuity's market capitalization chart represents the value of an early-stage biotech company focused on cancer diagnostics and treatment. Its valuation is entirely dependent on the success of its CELsignia diagnostic platform and clinical trials of therapeutic drugs. Sharp fluctuations in the chart are a direct market reaction to any scientific data the company releases.
CELC - Share of the company's market capitalization Celcuity Inc. within the market segment - Cancer analysis
Celcuity Inc. is a biotech company whose market share is based on its unique platform for analyzing live tumor cells. Its market capitalization reflects the potential of this technology to help identify the most effective treatments for cancer patients.
Market capitalization of the market segment - Cancer analysis
The graph below shows the total value of the oncology diagnostics sector. Celcuity occupies a unique niche within it, developing tests to select the most effective therapy for each individual patient. The potential of this market is enormous, as personalized medicine is the future of oncology, and Celcuity strives to be a key part of it.
Market capitalization of all companies included in a broad market index - GURU.Markets
Celcuity is a biotech company developing a platform for selecting the most effective therapy for cancer patients. Its market cap is a bet on the future of personalized medicine in cancer treatment, and its weight on the chart reflects the hope for a breakthrough in this field.
Book value capitalization of the company, segment and market as a whole
CELC - Book value capitalization of the company Celcuity Inc.
Celcuity's book value is the capital raised to develop its innovative diagnostic platform, CELsignia, which helps determine the most effective treatment for cancer patients. The chart is a financial timeline for a biotech company whose primary goal is to turn investments into working technology.
CELC - Share of the company's book capitalization Celcuity Inc. within the market segment - Cancer analysis
Celcuity develops new cancer diagnostic methods, which require cutting-edge laboratories. The chart shows the company's share of the biotech sector's actual R&D assets. This is its scientific infrastructure, where tests are created that could change approaches to cancer treatment.
Market segment balance sheet capitalization - Cancer analysis
Celcuity Inc. is a cell analysis company, making its model intellectually rather than capital-intensive. Its value lies in its unique diagnostic platform, not its manufacturing capabilities. Compared to the healthcare sector as a whole, its "light" balance sheet is typical of companies focused on R&D and diagnostics.
Book value of all companies included in the broad market index - GURU.Markets
Celcuity's assets are not drugs, but a cutting-edge diagnostic platform that enables individualized cancer treatment for each patient. The company's balance sheet reflects the value of its unique technology and data. The chart shows how much capital is invested in creating a tool that makes cancer treatment more precise and effective.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Celcuity Inc.
Celcuity is a biotech company developing new cancer diagnostic methods. Its market value is a multiple of its book value, as investors are investing in the scientific platform rather than in its assets. The chart reflects investor expectations about whether its technology will transform approaches to cancer treatment and generate billions in revenue.
Market to book capitalization ratio in a market segment - Cancer analysis
Celcuity is a biotech company developing diagnostic tests for cancer treatment selection. Its value reflects the hope for future approvals and commercialization. This chart demonstrates how investor expectations for its scientific platform far exceed the book value of its lab equipment.
Market to book capitalization ratio for the market as a whole
Celcuity is a biotech company developing cancer diagnostics. Its value is determined solely by the potential of its scientific platform and the success of future tests. This chart shows an extreme case where the market capitalization is almost a pure bet on a future scientific breakthrough with minimal book value.
Debts of the company, segment and market as a whole
CELC - Company debts Celcuity Inc.
Celcuity is a biotech company developing diagnostic tests and targeted therapies for cancer treatment. Funding breakthrough oncology research requires significant resources. This chart illustrates how the company uses capital to advance its innovative developments through complex and expensive clinical trials.
Market segment debts - Cancer analysis
Celcuity Inc. is a biotech company developing diagnostic tests for oncology. Funding during the R&D phase is crucial. This chart illustrates the company's financial strategy, showing whether it leverages funds to accelerate clinical trials or relies solely on equity capital, which is typical in the industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Celcuity Inc.
Celcuity is a biotech company developing new diagnostic methods and targeted therapies for cancer treatment. This chart shows its financial position at the clinical stage. The lack of debt and reliance on equity are typical for companies whose core business is expensive scientific research and clinical trials.
Market segment debt to market segment book capitalization - Cancer analysis
Celcuity is a biotech company focused on cancer diagnostics, which requires significant and risky investments in research. The chart shows the level of leverage in the oncology diagnostics sector. This allows investors to assess how Celcuity's capital raising strategy aligns with the risks and development timelines in this field.
Debt to book value of all companies in the market
Celcuity is an early-stage biotech company. The chart shows the debt burden for the entire market. This allows investors to appreciate the fundamental difference in funding: while the overall market can increase or decrease debt, companies like Celcuity rely on venture capital and research success.
P/E of the company, segment and market as a whole
P/E - Celcuity Inc.
For Celcuity, a biotech developing diagnostics for cancer treatment selection, this chart is a clear bet on innovation. Investors value its current earnings high because they are buying into the potential of its CELsignia platform. The chart's movement reflects trial results and partnership news, not current cash flows.
P/E of the market segment - Cancer analysis
This chart shows the average valuation for the biotech diagnostics sector—Celcuity's benchmark. This is an industry where investors evaluate the potential of a technology to transform medicine. Comparing Celcuity's valuation to the industry average helps us understand whether the market views its cancer therapy platform as more promising than competitors' offerings.
P/E of the market as a whole
Celcuity develops diagnostic tests that help select targeted therapies for cancer patients. The company's success depends on clinical trials and the acceptance of its tests by doctors. This chart shows the overall risk appetite of investors in biotech. It helps them understand whether they are willing to finance Celcuity's long and expensive journey to market, believing in its scientific approach.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Celcuity Inc.
Celcuity is a biotech company developing new methods for diagnosing and treating cancer. Its value is entirely dependent on the success of clinical trials. This chart reflects analysts' and investors' expectations for future research breakthroughs that could lead to blockbuster oncology treatments and exponential profit growth.
%20P%2FE%20Celcuity%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Celcuity-Inc.&v=1772592693547 "Chart of the company's future (projected) P/E Celcuity Inc.")
Future (projected) P/E of the market segment - Cancer analysis
Celcuity is a biotech company developing a platform for cancer diagnostics and treatment selection. Its valuation relative to other oncology companies reflects investor expectations for its innovative approach. A high valuation may indicate confidence in the company's ability to change the treatment paradigm by offering personalized solutions for patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772592693643 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Celcuity is a biotech company developing new diagnostics and targeted cancer therapies. Its valuation is entirely dependent on the success of clinical trials and investor confidence in its scientific platform. This chart reflects the overall market risk appetite, which is a key factor in funding long-term, high-risk biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772592693695 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Celcuity Inc.
Celcuity is a biotech company developing a platform for cancer diagnostics and treatment selection. The financial metrics shown in the chart primarily consist of research and development expenses. Successful completion of clinical trials and partnerships with pharmaceutical companies will be key to future growth.
Profit of companies in the market segment - Cancer analysis
Celcuity is a biotech company developing diagnostic tests for more effective cancer treatment. But how profitable is this field? This chart shows the total profitability of companies involved in oncology diagnostics. It reveals whether this biotech segment is financially successful or an area of high risk and R&D costs.
Overall market profit
Celcuity develops cutting-edge cancer diagnostics that help select targeted therapies. Like many research-stage biotech companies, Celcuity's earnings performance is secondary to this chart. Its primary value drivers are successful clinical trials and scientific breakthroughs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Celcuity Inc.
Celcuity develops diagnostic tests that help determine the most effective cancer treatments for individual patients. The company's future profitability depends entirely on the success of clinical trials and the subsequent acceptance of its tests by the medical community. This chart represents analysts' assessment of the likelihood of these innovations becoming standard in oncology.
%20profit%20of%20the%20company%20Celcuity%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Celcuity-Inc.&v=1772592693850 "Graph of future (projected) profit of the company Celcuity Inc.")
Future (predicted) profit of companies in the market segment - Cancer analysis
Celcuity is a biotech company developing a platform for diagnostics and targeted therapy selection for cancer patients. Their goal is to personalize cancer treatment. This chart shows forecasts for the oncodiagnostics segment. It helps assess the potential contribution of Celcuity's technology to industry profitability if it proves effective in treatment selection.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772592693873 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Celcuity Inc. is a biotechnology company developing diagnostic tests for targeted cancer therapy. The overall economic climate, illustrated by this chart, influences healthcare funding and R&D. Stable economic growth ensures investment in advanced medicine and allows healthcare systems to finance Celcuity's innovative tests.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772592693881 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Celcuity Inc.
Celcuity is a diagnostics company developing tests for personalized cancer treatment. With minimal current revenue, this metric reflects investor confidence in its scientific platform. The graph shows how much the market is willing to pay for the potential of its tests to become a standard in oncology and generate significant sales in the future.
P/S market segment - Cancer analysis
Celcuity develops diagnostic tests that help determine the most effective cancer treatments for individual patients. This chart reflects the average valuation in the medical diagnostics sector. It allows us to assess how investors perceive the potential of Celcuity's technology to transform cancer treatment compared to other companies.
P/S of the market as a whole
Celcuity Inc. develops diagnostic tests that help select personalized therapies for cancer patients. The company's revenue depends on the successful implementation of these tests in clinical practice. This chart shows how the market views medical innovations overall and compares Celcuity's valuation with average revenue multiples.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Celcuity Inc.
Celcuity is a biotech company developing a platform for cancer diagnostics and treatment selection. Its valuation is based on the future commercial success of its diagnostic tests and proprietary drugs. The chart reflects investors' belief that the company's technology will significantly improve treatment outcomes, leading to high future revenues.
%20P%2FS%20Celcuity%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Celcuity-Inc.&v=1772592694094 "The graph of the company's future (projected) P/S Celcuity Inc.")
Future (projected) P/S of the market segment - Cancer analysis
Celcuity is a biotech company developing diagnostic tests and targeted therapies for cancer treatment. Its platform enables the selection of the most effective treatment for each patient. This chart shows how investors estimate Celcuity's future revenue from its innovative solutions compared to other oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772592694204 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
This reflects investors' faith in the future of biotechnology. For Celcuity, which develops diagnostic tests for targeted cancer therapy, this is an indicator of the investment climate. Market optimism allows it to attract funding for research needed to develop tests that help doctors choose the most effective treatment for each patient.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772592694210 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Celcuity Inc.
Celcuity is a biotech company developing a cell-based analysis platform (CELsignia) to identify disease drivers in cancer patients that are undetectable by standard tests. This chart shows revenue from partnerships and testing services. As the company grows, it will reflect sales of its own targeted therapies.
Sales of companies in the market segment - Cancer analysis
Celcuity is a biotech company developing diagnostic tests for targeted cancer therapy. This graph illustrates the growth of the oncology diagnostics market. Celcuity is at the forefront of personalized medicine, and its innovative platforms help determine which patients will benefit from which treatments, driving the entire industry forward.
Overall market sales
Celcuity Inc. is a biotechnology company developing diagnostic tests for targeted cancer therapy. Its success depends on medical innovation and healthcare spending. The overall economic environment, reflected in the graph, influences the level of R&D funding and the introduction of new medical technologies into clinical practice.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Celcuity Inc.
Celcuity is a biotech company developing a platform for diagnostics and targeted therapy for cancer. Future commercial success depends on technology validation and partnerships with pharmaceutical companies. This chart reflects analysts' belief in the breakthrough potential of Celcuity's diagnostic platform and its ability to transform approaches to cancer treatment.
%20sales%20of%20the%20company%20Celcuity%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Celcuity-Inc.&v=1772592694459 "Schedule of future (projected) sales of the company Celcuity Inc.")
Future (projected) sales of companies in the market segment - Cancer analysis
Celcuity is a biotech company developing a platform for diagnostics and treatment selection for oncology. This forecast illustrates expectations for the entire cancer analytics sector. It highlights the growth analysts anticipate in the field of personalized medicine, where Celcuity's ability to accurately identify the right patients for treatment is its greatest asset.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772592694544 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Celcuity Inc. is a biotech company developing a cell analysis platform to more accurately select therapies for cancer patients. Its future depends on successful clinical trials and the acceptance of its technology by the medical community. This graph, reflecting the overall state of the economy, influences the level of funding in the biotech sector and the pace of innovation.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772592694601 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Celcuity Inc.
Celcuity is a biotech company developing new diagnostic methods for more precise cancer treatment selection. The graph reflects the stage of active research investment. Negative values represent clinical trial expenses, which form the foundation for future test commercialization and potentially high profits.
Market segment marginality - Cancer analysis
Celcuity is a biotech company developing diagnostic tests to more accurately select cancer therapies. Its financial performance is driven by investments in research to validate the effectiveness of its platform. This chart helps understand Celcuity's operating model compared to other companies in the medical diagnostics and oncology fields.
Market marginality as a whole
Celcuity is a biotech company developing diagnostic tests for targeted cancer therapy. This overall profitability curve has virtually no impact on its business. Celcuity's future profitability will be determined by the accuracy of its tests, their acceptance in medical practice, and their ability to help doctors save lives, creating unique value in oncology.
Employees in the company, segment and market as a whole
Number of employees in the company Celcuity Inc.
Celcuity is a biotech company developing a platform for cancer diagnostics and treatment selection. The chart shows the size of the scientific and clinical teams. This growth is directly related to progress in research and clinical trials, bringing the company closer to bringing new treatments to market.
Share of the company's employees Celcuity Inc. within the market segment - Cancer analysis
Celcuity develops innovative cancer diagnostic tests, which require deep scientific expertise. This chart shows the percentage of leading biologists, oncologists, and laboratory diagnostics specialists the company attracts in its niche. It reflects the concentration of scientific talent needed to create breakthrough cancer treatments.
Number of employees in the market segment - Cancer analysis
Celcuity Inc. is a biotech company developing diagnostic tests that help determine which cancer patients will benefit most from specific targeted therapies. Their approach personalizes cancer treatment. This chart shows employment in the oncology diagnostics sector, illustrating how advances in personalized medicine are driving demand for specialists.
Number of employees in the market as a whole
Celcuity is a biotech company developing tests for targeted cancer therapy. It exemplifies the future of medicine, based on a personalized approach. Companies like these demand the highest scientific qualifications from their employees. Their development demonstrates how the healthcare sector is becoming increasingly science-intensive, changing the demands on specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Celcuity Inc. (CELC)
Celcuity is a biotech company developing diagnostic tests and targeted therapies for cancer treatment. This chart shows how the market values its scientific potential. The high market capitalization per employee reflects the value of its intellectual property and the hope that its developments will revolutionize personalized oncology.
%20of%20the%20company%20Celcuity%20Inc.%20(CELC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Celcuity-Inc.-CELC&v=1772592694874 "Chart of market capitalization per employee (in thousands of dollars) of the company Celcuity Inc. (CELC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Celcuity Inc. is a biotech company developing a cell analysis platform (CELsignia) for targeted cancer therapy and its own proprietary drugs. This chart shows the average market cap per employee in the sector. It helps assess the market's confidence in their diagnostic platform and R&D pipeline, based on the company's relatively small research staff.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772592694880 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Celcuity is a biotech company developing diagnostic tests and targeted therapies for cancer treatment. This chart shows the average market value generated by one specialist. It helps understand how the market values the intellectual capital and potential of scientific developments in oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772592694906 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Celcuity Inc. (CELC)
Celcuity is a biotech company developing diagnostic tests (CDx) for cancer treatment selection. It operates at the intersection of diagnostics and pharmacology. This graph likely represents the loss per employee, which is typical for R&D companies. It reflects the company's bet that its research team can create a breakthrough product.
%20Chart%20Celcuity%20Inc.%20(CELC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Celcuity-Inc.-CELC&v=1772592694925 "Company Profit Per Employee (in thousands of dollars) Chart Celcuity Inc. (CELC)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Celcuity is a biotech R&D company (cancer diagnostics and drugs). This chart shows the benchmark for "Cancer Analysis" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772592694965 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Celcuity is a biotech company developing a cell analysis platform (CELsignia) for cancer diagnostics and treatment selection. It's an R&D company. This chart likely represents the company's loss per employee—its "burn rate." It reflects how much the company spends on research and clinical trials per its scientific staff as it moves toward commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772592694975 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Celcuity Inc. (CELC)
Celcuity is a biotech company developing diagnostic tests for cancer treatment selection. This chart reflects the commercial potential of breakthrough medical technologies. It shows how the success of one or more key products can lead to explosive revenue growth generated by a small but highly valuable team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Celcuity-Inc.-CELC&v=1772592695026 "Sales chart per company employee Celcuity Inc. (CELC)")
Sales per employee in the market segment - Cancer analysis
Celcuity is a biotech company developing a cell analysis platform to help select targeted therapies for cancer patients. This is diagnostics. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial diagnostics companies and helps evaluate the effectiveness of Celcuity's workforce.
Sales per employee for the market as a whole
Celcuity is a clinical-stage biotech company developing diagnostic tests and targeted cancer therapies. The company has no commercial revenue yet; its core business is research. This metric currently doesn't reflect value. The entire scientific team is focused on the future success of clinical trials, not current sales.
Short shares by company, segment and market as a whole
Shares shorted by company Celcuity Inc. (CELC)
Celcuity is a biotech company developing targeted cancer therapies and diagnostic tests for their use. Like many companies in this sector, its future depends on the success of clinical trials. This chart shows the percentage of investors who are skeptical of the company's scientific data or doubt the regulatory approval of its drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Celcuity-Inc.-CELC&v=1772592695100 "Short Shares Chart for the Company Celcuity Inc. (CELC)")
Shares shorted by market segment - Cancer analysis
Celcuity Inc. is a biotech company developing a cell-based analysis platform (CELsignia) to detect cancer and select the most effective treatments for patients. This chart shows a general short position in the medical diagnostics sector. Its rise reflects investor doubts about the ability of companies in the sector to successfully commercialize new diagnostic tests.
Shares shorted by the overall market
Celcuity (CELC) is a clinical-stage biotech (cancer diagnostics). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives CELC of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Celcuity Inc. (CELC)
Celcuity (CELC) is a biotech company developing a cell analysis platform (CELx) for cancer diagnostics and the discovery of new treatments. They aim to understand why patients don't respond to therapy. This chart measures market momentum. In biotech, it often shows "overheated" (above 70) on positive trial data or "oversold" (below 30) amid delays or share price dilution.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Celcuity-Inc.-CELC&v=1772592695209 "RSI 14 indicator chart for the company's stock Celcuity Inc. (CELC)")
RSI 14 Market Segment - Cancer analysis
Celcuity (CELC) is a biotech company developing diagnostic tests (CELsignia) to identify the drivers of cancer in individual patients to help select targeted therapies. This chart measures the pulse of the Cancer Testing sector. It helps differentiate Celcuity's success from the overall "overheated" or "oversold" nature of the oncology diagnostics industry.
RSI 14 for the overall market
Celcuity, a cancer diagnostics company, is critically dependent on the sentiment shown by this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs, and cash-burning companies risk running out of money.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CELC (Celcuity Inc.)
Celcuity is a biotech company that uses its CELsignia platform to analyze live tumor cells to determine the most effective targeted therapy for patients. This chart reflects the collective expert consensus on the fair 12-month share price of CELC, based on the success of this approach.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CELC-Celcuity-Inc.&v=1772592695304 "A chart showing analyst consensus forecasts for the expected stock price. CELC (Celcuity Inc.)")
The difference between the consensus estimate and the actual stock price CELC (Celcuity Inc.)
Celcuity (CELC) is a biotech company developing a cell-based analysis platform (CELsignia) for targeted cancer therapy. This chart is a barometer of their R&D hopes. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their diagnostic platform and their proprietary drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CELC-Celcuity-Inc.&v=1772592695328 "A chart showing the difference between the consensus forecast and the actual stock price. CELC (Celcuity Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Celcuity is a biotech company that uses its CELsignia platform to analyze a patient's live tumor cells to determine the most effective targeted therapy. This chart shows general expectations for the oncology sector, reflecting experts' belief in personalized medicine.
Analysts' consensus forecast for the overall market share price
Celcuity (CELC) is a biotech company developing a new live cancer diagnostic platform to predict therapy response. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to fund unprofitable biotechs with high potential. Pessimism = risk aversion, and R&D capital dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Celcuity Inc.
Celcuity is a biotech company working at the intersection of cancer diagnostics and therapeutics. Their platform (CELx) helps analyze live tumor cells to determine the most effective treatment for patients. This graph is an evaluation of their diagnostic platform. It reflects their progress in clinical trials demonstrating that their approach improves treatment outcomes.
AKIMA Market Segment Index - Cancer analysis
Celcuity (CELC) is a clinical-stage biotech focused on cancer; the company uses its diagnostic platform (CELsignia) to discover new treatments for breast cancer and other tumors. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Celcuity's diagnostic (R&D + testing) approach differentiate it from the average pharma company?
The AKIM Index for the overall market
Celcuity is a biotech company developing diagnostic tests to analyze a patient's cancer cells to determine the most effective therapy. This chart, which reflects the market average, provides context. It helps assess how this innovative precision medicine story fits in with the overall economic trends affecting the healthcare sector.
